Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals — Technical Presentation (July 2022)

9 slides from Intercept Pharmaceuticals's technical presentation, Jul 7, 2022

  1. Slide 1: REGENERATE Topline Data

    REGENERATE Topline Data 07 July 2022 Click to add text Click to add text

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward - Looking Statements This presentation contains forward - looking statements, including, but not limited to, statements regarding: The progress, timing , and results of our REGENERATE clinical trial, including the safety and efficacy of obeticholic acid (“OCA”) for

  3. Slide 3: Topline Results Overview

    Topline Results Overview • The planned Interim Analysis of the REGENERATE F2 and F3 month 18 (M18) liver biopsies was conducted under a Consensus Methodology. • The same population of subjects, and the same biopsies that were read in the Original Analysis have been re - read under this new methodolo

  4. Slide 4: Demographics and Baseline Disease Characteristics (N=2477)

    Demographics and Baseline Disease Characteristics (N=2477) ▪ Characteristics were balanced acros s treatment groups ▪ Mean Age ~55 years ▪ ~60% female, 90% white ▪ Mean BMI ~34 kg/m 2 ▪ ~60 % with diabetes at BL ▪ 1 in 4 patients have mild renal insufficiency ▪ Biomarkers consistent with advanced di

  5. Slide 5: OCA 25 mg Antifibrotic Effect at M18 is Double the Effect of Placebo

    OCA 25 mg Antifibrotic Effect at M18 is Double the Effect of Placebo Statistical Significance and Clinical Relevance Now Demonstrated Twice EFFICACY: At least one stage improvement in fibrosis without worsening of NASH • Results from Consensus Methodology were consistent with the Original Analysis c

  6. Slide 6: Improvement of Fibrosis by ≥1 Stage without Worsening of NASH

    6 Improvement of Fibrosis by ≥ 1 Stage without Worsening of NASH 0.0 5.0 10.0 15.0 20.0 25.0 Original Analysis Consensus Method Read 11.9 23.1 17.6 22.4 14.1 22.4 Percent Responders Antifibrotic Effect of OCA Demonstrated at M18 through Two Independent Methodologies p=0.0002 p<0.0001 Placebo (N=311)

  7. Slide 7: Resolution of NASH with No Worsening of Fibrosis

    7 Resolution of NASH with No Worsening of Fibrosis 0 5 10 15 20 25 11.7 6.5 11.2 6.1 8.0 3.5 Original Analysis Consensus Method Read 11.7% 11.2 3.5% 6.5% NS NS Percent Responders Resolution of NASH for OCA 10 mg and OCA 25 mg at M18 Shows Consistent Effect Compared to Placebo Cohort 6.1 6.5 Placebo

  8. Slide 8: Robust Safety Dataset for Resubmission: 3.4-fold Increase in Exposure

    Robust Safety Dataset for Resubmission: 3.4 - fold Increase in Exposure Relative to Original NDA 8 Original NDA NDA Resubmission Data Cut Off 26 Oct 2018 31 Dec 2021 Number of Subjects (n) Randomized 1,968 2,480 (fully enrolled) Month 18 Visit 1,218 1995 Month 24 Visit ~300 1901 Month 48 Visit None

  9. Slide 9: Summary of Safety & Tolerability

    Summary of Safety & Tolerability • Treatment emergent adverse events (TEAEs), treatment emergent serious adverse events (TESAEs) and deaths were generally balanced across the OCA and placebo treatment groups. • The most common TEAE was pruritus (24% in placebo, 33% in OCA 10 mg and 55% in OCA 25 mg)

Intercept Pharmaceuticals — Technical Presentation (July 2022) on 6ix